FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2215349211> ?p ?o ?g. }

• W2215349211 endingPage "559" @default.
• W2215349211 startingPage "550" @default.
• W2215349211 abstract "BackgroundOff-pump coronary artery bypass (OPCAB) surgery carries a high risk for haemodynamic instability and perioperative organ injury. Favourable haemodynamic effects and organ-protective properties could render xenon an attractive anaesthetic for OPCAB surgery. The primary aim of this study was to assess whether xenon anaesthesia for OPCAB surgery is non-inferior to sevoflurane anaesthesia with regard to intraoperative vasopressor requirements.MethodsForty-two patients undergoing elective OPCAB surgery were enrolled in this prospective, single-blind, randomized controlled pilot trial. Patients were randomized to either xenon (50–60 vol%) or sevoflurane (1.1–1.4 vol%) anaesthesia. Primary outcome was intraoperative noradrenaline requirements necessary to achieve predefined haemodynamic goals. Secondary outcomes included safety variables such as the occurrence of adverse events (intraoperatively and during a 6-month follow-up after surgery) and the perioperative cardiorespiratory and inflammatory profile.ResultsBaseline and intraoperative data did not differ between groups. Xenon was non-inferior to sevoflurane, as xenon patients required significantly less noradrenaline intraoperatively to achieve the predefined haemodynamic goals {geometric mean 428 [95% confidence interval (CI) 312, 588] vs 1702 [1267, 2285] µg, P<0.0001}. No differences were found for safety. Significantly more sevoflurane patients developed postoperative delirium (POD) (hazard ratio 4.2, P=0.044). The average arterial pressure was lower in the sevoflurane group {median75 [interquartile range (IQR) 6] vs 72 [4] mmHg, P=0.002}. No differences were found for other haemodynamic parameters, the respiratory profile and the perioperative release of inflammatory cytokines, troponin T, serum protein S-100β and erythropoietin.ConclusionsCompared with sevoflurane, xenon anaesthesia allows a significant reduction in vasopressor administration in OPCAB surgery. Moreover, xenon anaesthesia was associated with a lower risk for POD, a finding that has to be confirmed in larger studies.Clinical trial registrationClinicalTrials.gov (NCT01757106) and EudraCT (2012-002316-12). Off-pump coronary artery bypass (OPCAB) surgery carries a high risk for haemodynamic instability and perioperative organ injury. Favourable haemodynamic effects and organ-protective properties could render xenon an attractive anaesthetic for OPCAB surgery. The primary aim of this study was to assess whether xenon anaesthesia for OPCAB surgery is non-inferior to sevoflurane anaesthesia with regard to intraoperative vasopressor requirements. Forty-two patients undergoing elective OPCAB surgery were enrolled in this prospective, single-blind, randomized controlled pilot trial. Patients were randomized to either xenon (50–60 vol%) or sevoflurane (1.1–1.4 vol%) anaesthesia. Primary outcome was intraoperative noradrenaline requirements necessary to achieve predefined haemodynamic goals. Secondary outcomes included safety variables such as the occurrence of adverse events (intraoperatively and during a 6-month follow-up after surgery) and the perioperative cardiorespiratory and inflammatory profile. Baseline and intraoperative data did not differ between groups. Xenon was non-inferior to sevoflurane, as xenon patients required significantly less noradrenaline intraoperatively to achieve the predefined haemodynamic goals {geometric mean 428 [95% confidence interval (CI) 312, 588] vs 1702 [1267, 2285] µg, P<0.0001}. No differences were found for safety. Significantly more sevoflurane patients developed postoperative delirium (POD) (hazard ratio 4.2, P=0.044). The average arterial pressure was lower in the sevoflurane group {median75 [interquartile range (IQR) 6] vs 72 [4] mmHg, P=0.002}. No differences were found for other haemodynamic parameters, the respiratory profile and the perioperative release of inflammatory cytokines, troponin T, serum protein S-100β and erythropoietin. Compared with sevoflurane, xenon anaesthesia allows a significant reduction in vasopressor administration in OPCAB surgery. Moreover, xenon anaesthesia was associated with a lower risk for POD, a finding that has to be confirmed in larger studies." @default.
• W2215349211 created "2016-06-24" @default.
• W2215349211 creator A5002766987 @default.
• W2215349211 creator A5005616431 @default.
• W2215349211 creator A5014251646 @default.
• W2215349211 creator A5020057938 @default.
• W2215349211 creator A5057463934 @default.
• W2215349211 creator A5067387152 @default.
• W2215349211 creator A5071130345 @default.
• W2215349211 creator A5073823013 @default.
• W2215349211 creator A5075515817 @default.
• W2215349211 creator A5089485062 @default.
• W2215349211 date "2015-10-01" @default.
• W2215349211 modified "2023-10-18" @default.
• W2215349211 title "Xenon anaesthesia for patients undergoing off-pump coronary artery bypass graft surgery: a prospective randomized controlled pilot trial" @default.
• W2215349211 cites W1544359545 @default.
• W2215349211 cites W1633272553 @default.
• W2215349211 cites W1847168837 @default.
• W2215349211 cites W1981066923 @default.
• W2215349211 cites W1985135396 @default.
• W2215349211 cites W1991864206 @default.
• W2215349211 cites W1993918979 @default.
• W2215349211 cites W1997185388 @default.
• W2215349211 cites W2010482008 @default.
• W2215349211 cites W2010493309 @default.
• W2215349211 cites W2010906979 @default.
• W2215349211 cites W2019636064 @default.
• W2215349211 cites W2021493948 @default.
• W2215349211 cites W2080004635 @default.
• W2215349211 cites W2081033553 @default.
• W2215349211 cites W2096592799 @default.
• W2215349211 cites W2097804942 @default.
• W2215349211 cites W2101960548 @default.
• W2215349211 cites W2107382304 @default.
• W2215349211 cites W2121117087 @default.
• W2215349211 cites W2123841491 @default.
• W2215349211 cites W2123920578 @default.
• W2215349211 cites W2128276995 @default.
• W2215349211 cites W2129503298 @default.
• W2215349211 cites W2131475566 @default.
• W2215349211 cites W2132547422 @default.
• W2215349211 cites W2135781589 @default.
• W2215349211 cites W2139026464 @default.
• W2215349211 cites W2139937737 @default.
• W2215349211 cites W2141710162 @default.
• W2215349211 cites W2145976395 @default.
• W2215349211 cites W2153387493 @default.
• W2215349211 cites W2158909369 @default.
• W2215349211 cites W2160707945 @default.
• W2215349211 cites W2163115719 @default.
• W2215349211 cites W2884313467 @default.
• W2215349211 cites W4247943214 @default.
• W2215349211 doi "https://doi.org/10.1093/bja/aev303" @default.
• W2215349211 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26385664" @default.
• W2215349211 hasPublicationYear "2015" @default.
• W2215349211 type Work @default.
• W2215349211 sameAs 2215349211 @default.
• W2215349211 citedByCount "38" @default.
• W2215349211 countsByYear W22153492112015 @default.
• W2215349211 countsByYear W22153492112016 @default.
• W2215349211 countsByYear W22153492112017 @default.
• W2215349211 countsByYear W22153492112018 @default.
• W2215349211 countsByYear W22153492112019 @default.
• W2215349211 countsByYear W22153492112020 @default.
• W2215349211 countsByYear W22153492112021 @default.
• W2215349211 countsByYear W22153492112022 @default.
• W2215349211 countsByYear W22153492112023 @default.
• W2215349211 crossrefType "journal-article" @default.
• W2215349211 hasAuthorship W2215349211A5002766987 @default.
• W2215349211 hasAuthorship W2215349211A5005616431 @default.
• W2215349211 hasAuthorship W2215349211A5014251646 @default.
• W2215349211 hasAuthorship W2215349211A5020057938 @default.
• W2215349211 hasAuthorship W2215349211A5057463934 @default.
• W2215349211 hasAuthorship W2215349211A5067387152 @default.
• W2215349211 hasAuthorship W2215349211A5071130345 @default.
• W2215349211 hasAuthorship W2215349211A5073823013 @default.
• W2215349211 hasAuthorship W2215349211A5075515817 @default.
• W2215349211 hasAuthorship W2215349211A5089485062 @default.
• W2215349211 hasBestOaLocation W22153492111 @default.
• W2215349211 hasConcept C119060515 @default.
• W2215349211 hasConcept C126322002 @default.
• W2215349211 hasConcept C141071460 @default.
• W2215349211 hasConcept C178853913 @default.
• W2215349211 hasConcept C2775901492 @default.
• W2215349211 hasConcept C2776452961 @default.
• W2215349211 hasConcept C2776820930 @default.
• W2215349211 hasConcept C2777953023 @default.
• W2215349211 hasConcept C2780069944 @default.
• W2215349211 hasConcept C2781453256 @default.
• W2215349211 hasConcept C3017915907 @default.
• W2215349211 hasConcept C31174226 @default.
• W2215349211 hasConcept C42219234 @default.
• W2215349211 hasConcept C71924100 @default.
• W2215349211 hasConcept C84393581 @default.
• W2215349211 hasConceptScore W2215349211C119060515 @default.
• W2215349211 hasConceptScore W2215349211C126322002 @default.
• W2215349211 hasConceptScore W2215349211C141071460 @default.
• W2215349211 hasConceptScore W2215349211C178853913 @default.

• next